transcend glp 1 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 1 production. GLP-1 Support - 6 Month

conducted a multicentre, double-blind, placebo-controlled study in 94 patients with painful cervical or lumbosacral neuropathies [47]

Ive already lost 22 lbs and feel more in control of my appetite than ever

Stop treatment and call a healthcare provider if you notice: Severe swelling in your hands, feet, or face Chest pain or shortness of breath Sudden vision changes Signs of an allergic reaction (rash, throat swelling, trouble breathing) Significant mood swings or depression Why Do These Side Effects Happen

Researchers also found the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023

Collectively, these findings indicate that reactive astrocytes cannot be ascribed a uniform role